Sellas Life Sciences Group Inc
SLS1.626USD
-0.034-2.05%
交易中 （美东）报价延迟15分钟
147.80M总市值
亏损市盈率 TTM
关于 Sellas Life Sciences Group Inc 公司
SELLAS Life Sciences Group, Inc. 是一家后期临床生物制药公司。该公司专注于开发用于治疗一系列癌症适应症的新型疗法。该公司的候选产品包括 galinpepimut-S (GPS)，一种针对 Wilms 肿瘤 1 (WT1) 抗原的肽免疫疗法，以及 SLS009，一种选择性小分子细胞周期蛋白依赖性激酶 9 (CDK9) 抑制剂。GPS 是一种由纪念斯隆凯特琳癌症中心 (MSK) 授权的癌症免疫治疗剂，针对存在于多种肿瘤类型中的 WT1 蛋白。GPS 具有作为单一疗法或与其他免疫治疗剂联合使用的潜力，可以治疗广泛的血液系统恶性肿瘤和实体瘤适应症。该公司正在开发 SLS009，该药物由 GenFleet Therapeutics (Shanghai), Inc. 授权，用于大中华区以外的全球所有治疗和诊断用途。
公司简介
公司代码SLS
公司名称Sellas Life Sciences Group Inc
上市日期Mar 12, 2008
CEODr. Angelos M. Stergiou, M.D.
员工数量15
证券类型Ordinary Share
年结日Mar 12
公司地址7 Times Square
城市NEW YORK
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编10036
电话16462005278
网址https://www.sellaslifesciences.com/
公司代码SLS
上市日期Mar 12, 2008
CEODr. Angelos M. Stergiou, M.D.
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Angelos M. Stergiou, M.D.
Dr. Angelos M. Stergiou, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
108.88K
-79.44%
Dr. Dragan Cicic, M.D.
Dr. Dragan Cicic, M.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
50.33K
-73.28%
Mr. John Thomas Burns, CPA
Mr. John Thomas Burns, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
48.60K
-77.19%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
30.40K
+192.31%
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
30.40K
+192.31%
Mr. Robert L. Van Nostrand, CPA
Mr. Robert L. Van Nostrand, CPA
Independent Director
Independent Director
20.40K
+96.15%
Dr. David A. Scheinberg, M.D., Ph.D.
Dr. David A. Scheinberg, M.D., Ph.D.
Independent Director
Independent Director
10.58K
-38.05%
Mr. John W. Varian
Mr. John W. Varian
Independent Chairman of the Board
Independent Chairman of the Board
10.40K
-38.46%
名称
名称/职务
职务
持股
持股变动
Dr. Angelos M. Stergiou, M.D.
Dr. Angelos M. Stergiou, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
108.88K
-79.44%
Dr. Dragan Cicic, M.D.
Dr. Dragan Cicic, M.D.
Senior Vice President, Chief Development Officer
Senior Vice President, Chief Development Officer
50.33K
-73.28%
Mr. John Thomas Burns, CPA
Mr. John Thomas Burns, CPA
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
48.60K
-77.19%
Ms. Jane Wasman, J.D.
Ms. Jane Wasman, J.D.
Independent Director
Independent Director
30.40K
+192.31%
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
30.40K
+192.31%
Mr. Robert L. Van Nostrand, CPA
Mr. Robert L. Van Nostrand, CPA
Independent Director
Independent Director
20.40K
+96.15%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月23日 周三
更新时间: 7月23日 周三
持股股东
股东类型
持股股东
持股股东
占比
Anson Funds Management LP.
7.60%
The Vanguard Group, Inc.
2.85%
Geode Capital Management, L.L.C.
0.82%
Susquehanna International Group, LLP
0.69%
BlackRock Institutional Trust Company, N.A.
0.44%
Other
87.61%
持股股东
持股股东
占比
Anson Funds Management LP.
7.60%
The Vanguard Group, Inc.
2.85%
Geode Capital Management, L.L.C.
0.82%
Susquehanna International Group, LLP
0.69%
BlackRock Institutional Trust Company, N.A.
0.44%
Other
87.61%
股东类型
持股股东
占比
Hedge Fund
8.57%
Investment Advisor
4.65%
Investment Advisor/Hedge Fund
1.39%
Individual Investor
0.33%
Research Firm
0.19%
Bank and Trust
0.05%
Other
84.82%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
94
15.15M
15.18%
+3.74M
2025Q1
95
15.37M
15.79%
+4.85M
2024Q4
82
6.32M
8.71%
-3.29M
2024Q3
79
5.54M
8.62%
-2.91M
2024Q2
81
6.60M
15.25%
-2.78M
2024Q1
80
10.46M
22.59%
+5.00M
2023Q4
78
5.95M
19.06%
+1.91M
2023Q3
79
3.15M
11.52%
-1.61M
2023Q2
83
3.51M
12.82%
-1.46M
2023Q1
86
3.47M
12.66%
-413.28K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Anson Funds Management LP.
7.58M
7.6%
+6.39M
+535.69%
Mar 31, 2025
The Vanguard Group, Inc.
2.84M
2.85%
+546.46K
+23.83%
Mar 31, 2025
Geode Capital Management, L.L.C.
820.44K
0.82%
+86.89K
+11.85%
Mar 31, 2025
Susquehanna International Group, LLP
688.70K
0.69%
+688.70K
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
436.33K
0.44%
+3.52K
+0.81%
Mar 31, 2025
Citadel Advisors LLC
349.50K
0.35%
-135.81K
-27.98%
Mar 31, 2025
State Street Global Advisors (US)
277.03K
0.28%
+49.30K
+21.65%
Mar 31, 2025
Opus Capital Management, Inc.
239.50K
0.24%
+1.00K
+0.42%
Mar 31, 2025
Northern Trust Investments, Inc.
164.39K
0.16%
+29.70K
+22.05%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
iShares Micro-Cap ETF
0.04%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
占比0.04%
ProShares UltraPro Russell2000
占比0.01%
ProShares Hedge Replication ETF
占比0.01%
iShares Russell 2000 ETF
占比0.01%
iShares Russell 2000 Growth ETF
占比0.01%
Global X Russell 2000 ETF
占比0.01%
Proshares Ultra Russell 2000
占比0.01%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
